Trial Profile
Phase I/II Study of Lenalidomide (Revlimid), Thalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2020
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 20 Nov 2018 Status changed to completed.
- 18 Sep 2018 Status changed to discontinued.
- 30 Jul 2018 Status changed from active, no longer recruiting to completed.